| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Rudolph Nisi last filed a Form 4 in October 2017, as Director at SLS. Rudolph Nisi's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 42,918 shares of SLS. The SLS filings lean toward selling, a net 500 shares.
Rudolph Nisi has 7 Form 4 filings on record from June 2015 to October 2017, all as Director at SELLAS Life Sciences Group (SLS), 2015–2017.
The 8 reported transactions were 4 stock awards, 3 option or other derivative awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $273.
The only open-market sale was 500 shares of SLS at an average $0.55 on June 20, 2017, about $273.
Shares as reported in the last Form 4 for each company; the most recent is from October 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2017 | SLS Sellas Life Sciences Group, Inc. | Director | Sell | 500 | $0.55 | $273.05 | -3.3% |